Literature DB >> 34760301

Change in dysphagia and laryngeal function after radical radiotherapy in laryngo pharyngeal malignancies - a prospective observational study.

John M Mathew1, Ashutosh Mukherji1, Sunil Kumar Saxena2, Niranjan Vijayaraghavan1, Abhilash Menon1, Kombathula Sriharsha1, Malu Rafi3.   

Abstract

BACKGROUND: Intensity modulated radiotherapy (IMRT) has the perceived advantage of function preservation by reduction of toxicities in the treatment of laryngo-pharyngeal malignancies. The aim of the study was to assess changes in dysphagia from baseline (i.e. prior to start of treatment) at three and six months post treatment in patients with laryngo-pharyngeal malignancies treated with radical radiotherapy ± chemotherapy. Functional assessment of other structures involved in swallowing was also studied.
MATERIALS AND METHODS: 40 patients were sampled consecutively. 33 were available for final analysis. Dysphagia, laryngeal edema, xerostomia and voice of patients were assessed at baseline and at three and six months after treatment. Radiation was delivered with simultaneous integrated boost (SIB) using volumetric modulated radiation therapy (VMAT). Concurrent chemotherapy was three weekly cisplatin 100 mg/m2.
RESULTS: Proportion of patients with dysphagia rose significantly from 45.5% before the start of treatment to 57.6% at three months and 60.6% at six months post treatment (p = 0.019). 67% patients received chemotherapy and addition of chemotherapy had a significant correlation with dysphagia (p = 0.05, r = -0.336). Severity of dysphagia at three and six months correlated significantly with the mean dose received by the superior constrictors (p = 0.003, r = 0.508 and p = 0.024, r = 0.391) and oral cavity (p = 0.001, r = 0.558 and p = 0.003, r = 0.501). There was a significant worsening in laryngeal edema at three and six months post treatment (p < 0.01) when compared to the pre-treatment examination findings with 60.6% of patients having grade two edema at six months. Significant fall in the mean spoken fundamental frequency from baseline was seen at 6 months (p = 0.04), mean fall was 21.3 Hz (95% CI: 1.5-41 Hz) with significant increase in roughness of voice post treatment (p = 0.01).
CONCLUSION: There was progressive worsening in dysphagia, laryngeal edema and voice in laryngo-pharyngeal malignancies post radical radiotherapy ± chemotherapy.
© 2021 Greater Poland Cancer Centre.

Entities:  

Keywords:  dysphagia; function preservation; laryngeal function; radiotherapy; simultaneous integrated boost

Year:  2021        PMID: 34760301      PMCID: PMC8575359          DOI: 10.5603/RPOR.a2021.0078

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  34 in total

1.  CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines.

Authors:  Charlotte L Brouwer; Roel J H M Steenbakkers; Jean Bourhis; Wilfried Budach; Cai Grau; Vincent Grégoire; Marcel van Herk; Anne Lee; Philippe Maingon; Chris Nutting; Brian O'Sullivan; Sandro V Porceddu; David I Rosenthal; Nanna M Sijtsema; Johannes A Langendijk
Journal:  Radiother Oncol       Date:  2015-08-13       Impact factor: 6.280

2.  The effect of head and neck radiation therapy on voice quality.

Authors:  D J Hoyt; J W Lettinga; K A Leopold; S R Fisher
Journal:  Laryngoscope       Date:  1992-05       Impact factor: 3.325

3.  Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial.

Authors:  A Sharma; B K Mohanti; A Thakar; S Bahadur; S Bhasker
Journal:  Ann Oncol       Date:  2010-04-28       Impact factor: 32.976

4.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

5.  Dosimetric predictors of laryngeal edema.

Authors:  Giuseppe Sanguineti; Prashanth Adapala; Eugene J Endres; Collin Brack; Claudio Fiorino; Maria Pia Sormani; Brent Parker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-29       Impact factor: 7.038

Review 6.  Systematic review and meta-analysis of the impact of dosimetry to dysphagia and aspiration related structures.

Authors:  Emma Kristen Charters; Hans Bogaardt; Amy L Freeman-Sanderson; Kirrie J Ballard
Journal:  Head Neck       Date:  2019-01-24       Impact factor: 3.147

7.  Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.

Authors:  Hale B Caglar; Roy B Tishler; Megan Othus; Elaine Burke; Yi Li; Laura Goguen; Lori J Wirth; Robert I Haddad; Carl M Norris; Laurence E Court; Donald J Aninno; Marshall R Posner; Aaron M Allen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-28       Impact factor: 7.038

Review 8.  Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation.

Authors:  Barbara A Murphy; Jill Gilbert
Journal:  Semin Radiat Oncol       Date:  2009-01       Impact factor: 5.934

Review 9.  Organ preservation strategies: Review of literature and their applicability in developing nations.

Authors:  Mitali Dandekar; Anil D'Cruz
Journal:  South Asian J Cancer       Date:  2014-07

10.  DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Authors:  Imran Petkar; Keith Rooney; Justin W G Roe; Joanne M Patterson; David Bernstein; Justine M Tyler; Marie A Emson; James P Morden; Kathrin Mertens; Elizabeth Miles; Matthew Beasley; Tom Roques; Shreerang A Bhide; Kate L Newbold; Kevin J Harrington; Emma Hall; Christopher M Nutting
Journal:  BMC Cancer       Date:  2016-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.